Abstract
Background:
Since the first documentation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there has been a notable emphasis on it in a brief period, especially as the mortality rate and confirmed cases steadily rise. The rapid and accurate laboratory identification of an ongoing COVID-19 infection is essential for efficient pandemic control. For diagnostic purposes, various testing methods have been developed to detect the severity of COVID-19. These diagnostic methods play a crucial role in identifying and managing the spread of the virus within communities worldwide.Methods:
This cross-sectional observational study was conducted from February to June 2020, spanning four months. Patient clinical records and laboratory biomarkers data were collected.Results:
In this study, 263 patients were involved, with an average age of 59.38 ± 15.26 years, and 51.3% of them (135 patients) were male. The typical hospital stay was 9.25 ± 6.9 days. The patients were divided into three groups: Those who survived (49.4%), those receiving treatment (4.9%), and those who did not survive (45.6%), with all treated patients surviving. An important connection was observed between serum lactate dehydrogenase (LDH), creatine phosphokinase (CPK), urea, leukocytosis, lymphopenia, high polymorphonuclear neutrophil (PMN) counts, and poor patient outcomes (P-value < 0.05). Elevated aspartate transaminase (AST) levels also showed a close relationship with adverse outcomes (P-value = 0.05). Furthermore, most patients with hyponatremia, high fasting blood glucose, and elevated serum creatinine levels did not survive, despite lacking statistical significance.Conclusions:
Serum biomarkers serve as prognostic indicators for the severity of COVID-19 patients. Leveraging these markers aids in promptly diagnosing patients at high mortality risk and facilitates more effective treatments in the disease's initial phases. These biomarkers can help healthcare providers identify patients at higher risk of complications and guide the implementation of targeted interventions to improve patient outcomes.Keywords
COVID-19 Lactate Dehydrogenase Patient Outcomes Biomarkers Disease Severity
1. Background
Since December 2019, shortly after detecting the first coronavirus disease 2019 (COVID-19) patient in Wuhan, China, the world has faced a new pandemic caused by a novel Coronavirus (CoV) variant. Coronavirus belongs to the order Nidovirales and has the largest ribonucleic acid (RNA) genome (1, 2). COVID-19 causes a wide range of symptoms, from mild respiratory illness (fever, body aches, dry cough) to severe pneumonia, acute respiratory distress syndrome (ARDS), and death. As the World Health Organization (WHO) has noted, this novel CoV, SARS-CoV-2, has emerged as a global health concern (3, 4).
According to guidelines from WHO and the Centers for Disease Control and Prevention, chest radiography and lung computed tomography (CT) scans are essential diagnostic methods during the pandemic. Additionally, evaluating various biomarkers for prognosis and treatment response in COVID-19 patients has become critical (5, 6). Typically, patients with severe or critical COVID-19 exhibit hematologic changes, including lymphocytopenia and a reduction in monocytes, basophils, and eosinophils, along with a significant rise in leukocytes, neutrophils, and the neutrophil-to-lymphocyte ratio (NLR). These alterations reflect an imbalanced immune response in severe cases (7, 8).
Lymphocytopenia is commonly observed in severe cases and is believed to result from direct viral attack on these cells. In contrast, the elevated levels of leukocytes, neutrophils, and NLR indicate an escalated inflammatory response. Neutrophils, while essential in infection defense, can cause tissue damage and organ dysfunction when excessively elevated. The increased NLR highlights a dysregulated pro-inflammatory and anti-inflammatory balance, making these biomarkers crucial for early detection of severe illness (9, 10).
Additionally, biochemical markers such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine, D-dimer levels, extended prothrombin time, and inflammatory markers including lactate dehydrogenase (LDH), pro-BNP, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP), are often elevated in patients with severe COVID-19 (7, 8, 11). These biomarkers, expressed in various human cells (heart, liver, muscle, kidney, lung, and bone marrow), are indicators of acute or chronic tissue damage (9-11).
According to most studies, these markers correlate with respiratory function and are predictors of respiratory failure in COVID-19 patients. Elevated inflammatory biomarkers have been associated with mechanical ventilation requirements, ICU admission, and higher mortality. Therefore, they are valuable tools for early detection, respiratory monitoring, and timely intervention (12-14).
Preliminary data show significant differences in inflammatory marker levels between patients with acute and non-acute COVID-19 conditions (15-17). Longitudinal studies have demonstrated the importance of tracking these markers over time to assess disease progression and guide clinical management, emphasizing their predictive value for respiratory failure and overall prognosis in COVID-19 patients.
Biochemical and inflammatory markers are key tools for identifying patients at high risk of severe outcomes. Their regular monitoring enables healthcare professionals to make informed decisions regarding patient care and early intervention.
2. Methods
2.1. Patients and Data Collection
This observational, cross-sectional study evaluated all patients admitted to the ICU from February to June 2020, following a confirmed diagnosis of COVID-19 infection. During admission, clinical data, including sex, age, outcome, and laboratory parameters, were documented.
Based on the patient's clinical condition, age, comorbidities, medical history, medication, vital signs, and symptoms, an internal medicine or infectious specialist decides to hospitalize a patient.
ICU admission was based on at least one of the following criteria:
(1) Respiratory distress with a respiratory rate ≥ 30/min, PiO2/FiO2 ratio < 200, or PaO2 < 60 mm Hg, or SpO2 < 90% with FiO2 > 50%;
(2) Hemodynamic instability with a mean arterial pressure (MAP) < 60 mm Hg, unresponsive to 500 mL intravenous fluid administration, requiring vasopressors or inotropes;
(3) Neurological disorder requiring airway support due to a low level of consciousness;
(4) Multiple organ dysfunction requiring organ support (18).
The definitive diagnosis of COVID-19 was confirmed by SARS-CoV-2 RT-PCR testing and evidence of lung involvement on CT scan.
Inclusion criteria: Definite diagnosis of COVID-19 by RT-PCR and lung CT findings consistent with COVID-19 infection.
Exclusion criteria: Presence of cardiovascular, renal, or liver diseases; hemolytic or megaloblastic anemia; diabetes; or cancer.
2.2. Statistical Analysis
Data were analyzed using SPSS 18.0 software (IBM, Armonk, NY, USA). Quantitative variables were described using the mean ± standard deviation. Qualitative variables were reported using frequency distributions. The chi-square test was used to analyze qualitative variables. Independent t-tests were employed to compare mean values between groups when the data were normally distributed. For abnormally distributed data, the non-parametric Mann-Whitney test (Kruskal-Wallis) was used. A P-value < 0.05 was considered statistically significant.
2.3. Ethics Approval
This research adhered to the principles of the Declaration of Helsinki and was conducted with the approval of the Ethics Committee of Golestan University of Medical Sciences, with ethics code IR.GOUMS.REC.1399.349.
3. Results
After applying the inclusion criteria, 263 ICU-admitted patients diagnosed with COVID-19 were included in this study. Diagnosis was based on a positive RT-PCR test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and CT scan findings indicative of COVID-19 infection (Table 1). The mean age of the patients was 59.38 ± 15.26 years, with the youngest being 23 years old and the oldest being 94 years old. The average hospitalization duration was 9.25 ± 6.9 days.
Characteristics of Patients with COVID-19 a
| Variables | Result |
|---|---|
| Gender | |
| Male | 135 (51.3) |
| Female | 128 (48.7) |
| Age (y) | 59.38 ± 15.26 |
| Hospitalization duration (day) | 9.25 ± 6.9 |
| Outcome | |
| Non-survivors | 120 (45.6) |
| Survivors | 130 (49.4) |
| Under Treatment | 13 (4.9) |
Among the participants, 51.3% (135 patients) were male, and 48.7% (128 patients) were female. Of the total patients, 120 (45.6%) did not survive, 130 (49.4%) survived, and 13 (4.9%) were still under treatment at the time of data collection. All patients who were under treatment survived. At diagnosis, patients were categorized into three groups: Discharged, under treatment, and non-survivors. Age, gender, and hospitalization duration did not show significant differences between non-survivors and survivors (Table 2).
Demographic, Characteristics, and Outcomes of COVID-19 Patients Included in the Study
| Variables | Outcome | P-Value | ||
|---|---|---|---|---|
| Survivors | Under Treatment | Non-survivors | ||
| Gender | 0.16 | |||
| Female | 66 (51.6) | 3 (2.3) | 59 (46.1) | |
| Male | 64 (47.4) | 10 (7.4) | 61 (45.2) | |
| Age (y) | 0.33 | |||
| > 60 | 63 (50.8) | 5 (4) | 56 (45.2) | |
| 40 - 60 | 52 (48.6) | 4 (3.7) | 51 (47.4) | |
| < 40 | 15 (46.9) | 4 (12.5) | 13 (40.6) | |
| Admission days | 0.88 | |||
| > 9.25 | 48 (51.1) | 5 (5.3) | 41 (43.6) | |
| < 9.25 | 82 (45.5) | 8 (4.7) | 79 (46.7) | |
The outcomes of hospitalized COVID-19 patients were assessed in relation to their serum laboratory marker levels, as detailed in Table 3. Hematologic parameters were examined, revealing a statistically significant relationship between white blood cell (WBC) counts, levels of polymorphonuclear neutrophils (PMNs), lymphocyte percentages, and patient mortality (P-value < 0.05). Specifically, patients with leukocytosis, elevated PMN levels, and lymphopenia exhibited poorer clinical outcomes, while those with lower WBC counts and PMN percentages showed better survival rates.
Laboratory Biomarkers and Outcomes of COVID-19 Patients Included in the Study a
| Variables and Categories | Outcome | Mean | P-Value b | ||
|---|---|---|---|---|---|
| Survivors | Under Treatment | Non-survivors | |||
| LDH (IU/L) | 812.41 ± 438.6 | < 0.05 | |||
| > 812 | 15 (15.5) | 2 (2.1) | 80 (82.5) | ||
| < 812 | 105 (70) | 10 (6.7) | 35 (23.3) | ||
| WBC (109/L) | 9.71 ± 9.82 | < 0.05 | |||
| > 9.71 | 39 (38.6) | 3 (3) | 59 (58.4) | ||
| < 9.71 | 91 (56.2) | 10 (6.2) | 61 (37.7) | ||
| PMN | 80.23 ± 9.28 | < 0.05 | |||
| > 80.23 | 55 (39.6) | 5 (3.6) | 79 (56.8) | ||
| < 80.23 | 75 (61) | 8 (6.5) | 40 (32.5) | ||
| Lymphocyte | 14.33 ± 8.71 | < 0.05 | |||
| > 14.33 | 71 (67) | 7 (6.6) | 28 (26.4) | ||
| < 14.33 | 59 (37.8) | 6 (3.8) | 91 (58.3) | ||
| PLT (109/L) | 208.52 ± 97.04 | 0.58 | |||
| > 208.52 | 56 (53.3) | 5 (4.8) | 44 (41.9) | ||
| < 208.52 | 74 (49.4) | 8 (5.1) | 76 (48.1) | ||
| Hb (g/dL) | 11.62 ± 1.87 | 0.79 | |||
| > 11.62 | 71 (49.7) | 6 (4.2) | 66 (46.2) | ||
| < 11.62 | 57 (49.1) | 7 (6) | 52 (44.8) | ||
| Urea (mg/dL) | 68.18 ± 57.98 | < 0.05 | |||
| > 20 | 109 (46.4) | 11 (4.7) | 115 (48.9) | ||
| < 20 | 20 (74.1) | 2 (7.4) | 27 (18.5) | ||
| Creatinine (mg/dL) | 1.64 ± 1.5 | 0.08 | |||
| > 1.3 | 32 (39) | 5 (6.1) | 45 (54.9) | ||
| < 1.3 | 97 (53.9) | 8 (4.4) | 75 (41.7) | ||
| Na (mEq/L) | 136.31 ± 5.16 | 0.09 | |||
| > 145 | 1 (7.7) | 0 (0) | 12 (92.3) | ||
| 135 - 145 | 78 (49.4) | 8 (5) | 73 (45.9) | ||
| < 135 | 50 (56.2) | 5 (5.6) | 34 (38.2) | ||
| K (mEq/L) | 4.39 ± 0.77 | 0.47 | |||
| > 5.5 | 8 (40) | 0 (0) | 12 (60) | ||
| 3.5 - 5.5 | 114 (51.1) | 12 (5.4) | 97 (43/5) | ||
| < 3.5 | 7 (38.9) | 1 (5.6) | 10 (55.6) | ||
| FBS (mg/dL) | 185.32 ± 100.83 | 0.13 | |||
| > 100 | 51 (40.5) | 4 (6.7) | 71 (56.3) | ||
| < 100 | 17 (56.7) | 2 (6.7) | 11 (36.7) | ||
| CPK (mcg/L) | 594.34 ± 2409.92 | < 0.05 | |||
| > 120 | 43 (38.4) | 5 (4.5) | 64 (57.1) | ||
| < 120 | 32 (61.5) | 2 (3.8) | 18 (34.6) | ||
| Albumin (g/dL) | 3.46 ± 0.56 | 0.76 | |||
| > 3.5 | 37 (58.7) | 2 (3.2) | 24 (38.1) | ||
| < 3.5 | 31 (59.1) | 3 (5.8) | 18 (34.6) | ||
| AST (IU/L) | 60.51 ± 71.08 | 0.05 | |||
| > 60.51 | 15 (32.6) | 1 (2.2) | 30 (65.2) | ||
| < 60.51 | 54 (54) | 9 (9) | 37 (37) | ||
| ALT (IU/L) | 57.45 ± 81.15 | 0.51 | |||
| > 57.45 | 18 (48.6) | 1 (2.7) | 18 (48.6) | ||
| < 57.45 | 51 (46.8) | 9 (8.3) | 49 (45) | ||
| Alkp (IU/L) | 264.89 ± 239.63 | 0.65 | |||
| > 147 | 54 (48.6) | 9 (8.1) | 48 (43.2) | ||
| 44 - 147 | 14 (45.2) | 1 (3.2) | 16 (51.6) | ||
| < 44 | 0 (0) | 0 (0) | 1 (100) | ||
Additionally, significant associations were found between serum levels of urea, creatine phosphokinase, and lactate dehydrogenase and patient outcomes, with all showing statistically significant relationships (all P-values < 0.05). Patients with lower CPK and urea levels were more likely to survive compared to those with higher levels. Aspartate transaminase levels also showed a nearly significant relationship with patient outcomes (P-value = 0.05).
Moreover, a majority of patients with hypernatremia (92.3%), elevated fasting blood glucose levels (56.3%), and increased serum creatinine levels (54.9%) did not survive.
The mean serum LDH level at the time of diagnosis was 812.41 ± 438.6 IU/L. There was a statistically significant difference in LDH levels between the non-survived and survived groups. As the hospitalization duration extended from one to twelve days, serum LDH levels increased. In all cases, non-survivors exhibited higher LDH levels than survivors (Figures 1 and 2).
Comparison of median and interquartile range of lactate dehydrogenase levels in non-survivors and survivors during 12 consecutive days
Comparison of the mean serum lactate dehydrogenase level in non-survivors and survivors during 12 consecutive days
4. Discussion
COVID-19 is an infectious viral disease typically associated with local or systemic inflammation, which can damage several organs. Despite antiviral treatment and supportive care, the mortality rate from COVID-19 remains high. Organ and tissue damage during COVID-19 can result from excessive inflammation and uncontrolled immune activation. Consequently, inflammatory biomarkers such as neutrophils and CRP, and cellular enzymes like LDH and creatine phosphokinase, are critical indicators for diagnosing, monitoring, and predicting the prognosis of COVID-19 patients.
A study by Poggiali et al. (2020) reported that elevated LDH levels were an independent biomarker for poor prognosis in COVID-19 patients, correlated with respiratory function (PaO2/FiO2), and served as a predictor of respiratory failure (18, 19). Most studies have shown that LDH levels above 200 - 250 IU/L are linked to poor outcomes. Henry et al. (2020) indicated that LDH cut-off values between 245 and 253.2 U/L were associated with a significantly increased risk of mortality. In particular, LDH > 812 IU/L has been identified as a relevant factor in risk assessment for advanced COVID-19 and death. Our study also found that age or sex did not significantly affect the relationship between elevated LDH levels and poor prognosis, though these factors may contribute to increased COVID-19 severity and mortality, potentially confounding the association (17, 19).
Our research further demonstrated that LDH levels rose with the duration of hospitalization, with serum LDH levels increasing as patients’ hospital stays extended from one to twelve days. Elevated LDH has been identified as a powerful predictor for early recognition of lung injury and severe COVID-19 cases (19, 20).
We also observed that leukocytosis and elevated PMN levels were associated with organ damage and hypoxia. Studies have confirmed that these markers reach their highest levels in lung infections and respiratory failure and are linked to poor outcomes and mortality in COVID-19 patients. As such, leukocytosis and elevated PMN levels can be established as key predictive factors for early diagnosis of lung injury and severe respiratory infections, such as COVID-19 (21, 22). Additionally, lymphopenia has been observed in severe COVID-19 cases, further compromising immune responses and increasing vulnerability to secondary infections. Our findings suggest that individuals with lymphopenia are at higher risk of morbidity, mortality, and severe complications from COVID-19 (22, 23).
Elevated urea levels in COVID-19 patients indicate potential kidney damage or dysfunction. Although the exact cause remains unclear, it may result from direct viral effects on the kidneys or dehydration caused by fever, sweating, and reduced fluid intake (24-26).
In severe COVID-19, elevated CPK levels are often seen in patients with complications such as rhabdomyolysis. The cytokine storm syndrome that can occur in severe COVID-19 cases may lead to widespread inflammation, muscle breakdown, and increased CPK levels in the blood. Our research links elevated CPK levels to multi-organ failure, respiratory distress, and increased mortality risk in advanced COVID-19 cases. High CPK levels may indicate muscle damage and inflammation, signaling disease severity and poor outcomes (25-27).
Additionally, our research revealed a relationship between hypernatremia, elevated fasting blood glucose (FBS), and increased serum creatinine levels with higher mortality rates in COVID-19 patients, though these associations were not statistically significant. Hypernatremia may indicate dehydration, leading to organ dysfunction and worsening prognosis, while elevated FBS suggests undiagnosed or uncontrolled diabetes, a known risk factor for severe COVID-19. Elevated serum creatinine may reflect kidney dysfunction, further exacerbating the infection's effects (28-31).
Studies by Letelier et al. (2021) and Ponti et al. (2020) identified elevated levels of inflammatory serum markers (e.g., ESR, CRP, LDH), hepatic markers (AST, ALT), cardiac biomarkers (pro-BNP, CK-MB), and renal function indicators (urea, creatinine) in COVID-19 patients. Patients in more critical conditions exhibited significantly higher levels of these markers, correlating with increased likelihood of organ damage and further elevations in these biomarkers (32, 33).
4.1. Strengths and Limitations
The strength of our study lies in identifying serum biomarkers that help predict disease severity, guide treatment decisions, and monitor COVID-19 progression. By tracking these biomarkers, healthcare providers can gain valuable insights into the disease's underlying pathophysiology and tailor interventions accordingly. Studying biomarkers in ICU patients with COVID-19 provides critical information for improving patient outcomes. However, heterogeneity in results across studies could be attributed to differences in cut-off points, laboratory references, diagnostic tools, underlying diseases, and varying treatment methods. Additionally, variations in sample collection timing among patients could affect result accuracy.
4.2. Conclusions
This study investigated the impact of serum biomarkers on the prognosis of high-risk COVID-19 patients during hospitalization. Our findings suggest that elevated levels of LDH, CPK, urea, WBC, and PMN, as well as lymphopenia, are associated with an increased risk of in-hospital mortality and predict severe respiratory failure in COVID-19 patients. Monitoring these biomarkers during hospitalization could help identify patients at higher risk of adverse outcomes and improve clinical management. Early identification of these biomarkers can aid healthcare providers in stratifying high-risk COVID-19 patients for more intensive monitoring and timely interventions.
References
-
1.
El Zowalaty ME, Järhult JD. From SARS to COVID-19: A previously unknown SARS- related coronavirus (SARS-CoV-2) of pandemic potential infecting humans - Call for a One Health approach. One Health. 2020;9:100124. [PubMed ID: 32195311]. [PubMed Central ID: PMC7075990]. https://doi.org/10.1016/j.onehlt.2020.100124.
-
2.
Lashkarbolouk N, Mazandarani M, Pourghazi F, Eslami M, Khonsari NM, Ghonbalani ZN, et al. How did lockdown and social distancing policies change the eating habits of diabetic patients during the COVID-19 pandemic? A systematic review. Front Psychol. 2022;13:1002665. [PubMed ID: 36211913]. [PubMed Central ID: PMC9540372]. https://doi.org/10.3389/fpsyg.2022.1002665.
-
3.
Sahu P. Closure of Universities Due to Coronavirus Disease 2019 (COVID-19): Impact on Education and Mental Health of Students and Academic Staff. Cureus. 2020;12(4). e7541. [PubMed ID: 32377489]. [PubMed Central ID: PMC7198094]. https://doi.org/10.7759/cureus.7541.
-
4.
Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181-92. [PubMed ID: 30531947]. [PubMed Central ID: PMC7097006]. https://doi.org/10.1038/s41579-018-0118-9.
-
5.
Shi J, Li Y, Zhou X, Zhang Q, Ye X, Wu Z, et al. Lactate dehydrogenase and susceptibility to deterioration of mild COVID-19 patients: a multicenter nested case-control study. BMC Med. 2020;18(1):168. [PubMed ID: 32493370]. [PubMed Central ID: PMC7268591]. https://doi.org/10.1186/s12916-020-01633-7.
-
6.
Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17(9):543-58. [PubMed ID: 32690910]. [PubMed Central ID: PMC7370876]. https://doi.org/10.1038/s41569-020-0413-9.
-
7.
Bivona G, Agnello L, Ciaccio M. Biomarkers for Prognosis and Treatment Response in COVID-19 Patients. Ann Lab Med. 2021;41(6):540-8. [PubMed ID: 34108281]. [PubMed Central ID: PMC8203437]. https://doi.org/10.3343/alm.2021.41.6.540.
-
8.
Mortaz E, Bassir A, Dalil Roofchayee N, Dezfuli NK, Jamaati H, Tabarsi P, et al. Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra. Int Immunopharmacol. 2021;93:107407. [PubMed ID: 33631512]. [PubMed Central ID: PMC7826095]. https://doi.org/10.1016/j.intimp.2021.107407.
-
9.
Tan E, Song J, Deane AM, Plummer MP. Global Impact of Coronavirus Disease 2019 Infection Requiring Admission to the ICU: A Systematic Review and Meta-analysis. Chest. 2021;159(2):524-36. [PubMed ID: 33069725]. [PubMed Central ID: PMC7557272]. https://doi.org/10.1016/j.chest.2020.10.014.
-
10.
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-7. [PubMed ID: 32073213]. [PubMed Central ID: PMC7166509]. https://doi.org/10.1111/jth.14768.
-
11.
Mazandarani M, Sharififar R, Lashkarbolouk N, Ghorbani S. Evaluation of cardiac diagnostic tests findings based on pro-BNP levels in COVID-19 pregnant patients. BMC Infect Dis. 2023;23(1):790. [PubMed ID: 37957564]. [PubMed Central ID: PMC10644487]. https://doi.org/10.1186/s12879-023-08764-1.
-
12.
Rifai N. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics-E-Book: Tietz Textbook of Clinical Chemistry and Molecular Diagnostics-E-Book. 6th ed. Boston, Massachusetts: Elsevier Health Sciences; 2017.
-
13.
Huijgen HJ, Sanders GT, Koster RW, Vreeken J, Bossuyt PM. The clinical value of lactate dehydrogenase in serum: a quantitative review. Eur J Clin Chem Clin Biochem. 1997;35(8):569-79. [PubMed ID: 9298346].
-
14.
Szarpak L, Ruetzler K, Safiejko K, Hampel M, Pruc M, Kanczuga-Koda L, et al. Lactate dehydrogenase level as a COVID-19 severity marker. Am J Emerg Med. 2021;45:638-9. [PubMed ID: 33246860]. [PubMed Central ID: PMC7666711]. https://doi.org/10.1016/j.ajem.2020.11.025.
-
15.
Danese E, Montagnana M. An historical approach to the diagnostic biomarkers of acute coronary syndrome. Ann Transl Med. 2016;4(10):194. [PubMed ID: 27294090]. [PubMed Central ID: PMC4885896]. https://doi.org/10.21037/atm.2016.05.19.
-
16.
McFadden RG, Oliphant LD. Serum lactate dehydrogenase in interstitial lung disease. Chest. 1991;100(4):1182. [PubMed ID: 1914596]. https://doi.org/10.1378/chest.100.4.1182-b.
-
17.
Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am J Emerg Med. 2020;38(9):1722-6. [PubMed ID: 32738466]. [PubMed Central ID: PMC7251362]. https://doi.org/10.1016/j.ajem.2020.05.073.
-
18.
Poggiali E, Zaino D, Immovilli P, Rovero L, Losi G, Dacrema A, et al. Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients. Clin Chim Acta. 2020;509:135-8. [PubMed ID: 32531257]. [PubMed Central ID: PMC7282743]. https://doi.org/10.1016/j.cca.2020.06.012.
-
19.
Rashedi S, Keykhaei M, Pazoki M, Ashraf H, Najafi A, Kafan S, et al. Clinical significance of prognostic nutrition index in hospitalized patients with COVID-19: Results from single-center experience with systematic review and meta-analysis. Nutr Clin Pract. 2021;36(5):970-83. [PubMed ID: 34270114]. [PubMed Central ID: PMC8441695]. https://doi.org/10.1002/ncp.10750.
-
20.
Rostam SRK, Shekhany KAM, Smail HO. Comparative study of some biochemical parameters among of COVID-19 symptoms and non COVID-19 symptoms individuals. BIOVALENTIA: Biological Research Journal. 2020;6(2):9-14.
-
21.
Violetis OA, Chasouraki AM, Giannou AM, Baraboutis IG. COVID-19 Infection and Haematological Involvement: a Review of Epidemiology, Pathophysiology and Prognosis of Full Blood Count Findings. SN Compr Clin Med. 2020;2(8):1089-93. [PubMed ID: 32838152]. [PubMed Central ID: PMC7323879]. https://doi.org/10.1007/s42399-020-00380-3.
-
22.
Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834-47. [PubMed ID: 32282949]. [PubMed Central ID: PMC7262337]. https://doi.org/10.1002/ajh.25829.
-
23.
Kavsak PA, de Wit K, Worster A. Emerging key laboratory tests for patients with COVID-19. Clin Biochem. 2020;81:13-4. [PubMed ID: 32360478]. [PubMed Central ID: PMC7192114]. https://doi.org/10.1016/j.clinbiochem.2020.04.009.
-
24.
Ferrari D, Motta A, Strollo M, Banfi G, Locatelli M. Routine blood tests as a potential diagnostic tool for COVID-19. Clin Chem Lab Med. 2020;58(7):1095-9. [PubMed ID: 32301746]. https://doi.org/10.1515/cclm-2020-0398.
-
25.
Chen Z, Xu W, Ma W, Shi X, Li S, Hao M, et al. Clinical laboratory evaluation of COVID-19. Clin Chim Acta. 2021;519:172-82. [PubMed ID: 33939954]. [PubMed Central ID: PMC8086377]. https://doi.org/10.1016/j.cca.2021.04.022.
-
26.
Lai CKC, Lam W. Laboratory testing for the diagnosis of COVID-19. Biochem Biophys Res Commun. 2021;538:226-30. [PubMed ID: 33139015]. [PubMed Central ID: PMC7598306]. https://doi.org/10.1016/j.bbrc.2020.10.069.
-
27.
Shyu D, Dorroh J, Holtmeyer C, Ritter D, Upendran A, Kannan R, et al. Laboratory Tests for COVID-19: A Review of Peer-Reviewed Publications and Implications for Clinical Use. Mo Med. 2020;117(3):184-95. [PubMed ID: 32636542]. [PubMed Central ID: PMC7302033].
-
28.
Mair M, Singhavi H, Pai A, Singhavi J, Gandhi P, Conboy P, et al. A Meta-Analysis of 67 Studies with Presenting Symptoms and Laboratory Tests of COVID-19 Patients. Laryngoscope. 2021;131(6):1254-65. [PubMed ID: 33068023]. https://doi.org/10.1002/lary.29207.
-
29.
Shrestha AB, Sapkota UH, Shrestha S, Aryal M, Chand S, Thapa S, et al. Association of hypernatremia with outcomes of COVID-19 patients: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2022;101(51). e32535. [PubMed ID: 36595846]. [PubMed Central ID: PMC9794240]. https://doi.org/10.1097/md.0000000000032535.
-
30.
Xiang J, Wen J, Yuan X, Xiong S, Zhou X, Liu C, et al. Potential biochemical markers to identify severe cases among COVID-19 patients. MedRxiv. 2020. https://doi.org/10.1101/2020.03.19.20034447.
-
31.
Ok F, Erdogan O, Durmus E, Carkci S, Canik A. Predictive values of blood urea nitrogen/creatinine ratio and other routine blood parameters on disease severity and survival of COVID-19 patients. J Med Virol. 2021;93(2):786-93. [PubMed ID: 32662893]. [PubMed Central ID: PMC7405288]. https://doi.org/10.1002/jmv.26300.
-
32.
Letelier P, Encina N, Morales P, Riffo A, Silva H, Riquelme I, et al. Role of biochemical markers in the monitoring of COVID-19 patients. J Med Biochem. 2021;40(2):115-28. [PubMed ID: 33776561]. [PubMed Central ID: PMC7982290]. https://doi.org/10.5937/jomb0-29341.
-
33.
Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389-99. [PubMed ID: 32503382]. [PubMed Central ID: PMC7284147]. https://doi.org/10.1080/10408363.2020.1770685.